Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
September 20, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
GENEDRIVE PARTNERS WITH FIND TO EVALUATE A MOLECULAR DIAGNOSTIC KIT FOR HEPATITIS C VIRUS IN DECENTRALISED SETTINGS
August 08, 2018 02:00 ET
|
Genedrive PLC
GENEDRIVE PARTNERS WITH FIND TO EVALUATE A MOLECULAR DIAGNOSTIC KIT FOR HEPATITIS C VIRUS IN DECENTRALISED SETTINGS Evaluation studies of the...
Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus
April 03, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
– Company on track to commence patient enrollment and dosing in Q2 2018 – – Topline data from Phase 2a study expected in Q4 2018 – ATLANTA, GA and BOTHELL, WA, April 03,...
Cocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook
March 22, 2018 07:05 ET
|
Cocrystal Pharma, Inc.
–Company successfully completes uplisting to the NASDAQ Capital Market – –Company positioned to achieve clinical and regulatory milestones over the course of 2018– ATLANTA, GA and BOTHELL, WA, March...
UT Medical Center Announces Published Research Showing Evidence of Vast Hepatitis C Virus Transmission via Snorting Straws
July 28, 2016 09:42 ET
|
The University of Tennessee Medical Center
KNOXVILLE, Tenn., July 28, 2016 (GLOBE NEWSWIRE) -- Officials with The University of Tennessee Medical Center (UTMC) have announced evidence that the sharing of snorting utensils, such as straws, when...
Overstock.com CEO Dr. Patrick M. Byrne to Take Medical Leave of Absence
April 11, 2016 06:40 ET
|
Beyond, Inc.
SALT LAKE CITY, April 11, 2016 (GLOBE NEWSWIRE) -- Overstock.com, Inc. (NASDAQ:OSTK) today announced its founder and CEO, Patrick M. Byrne, will take a personal leave of absence for medical...
Patient Advocate Foundation Offers New CareLine for Hepatitis C Patients
January 05, 2015 10:05 ET
|
Patient Advocate Foundation
HAMPTON, Va., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Patient Advocate Foundation (PAF) – a national, non-profit organization providing professional case management services to patients facing...
CDC Recommends One-Time Hepatitis C Test for All Baby Boomers
August 16, 2012 12:52 ET
|
CDC Foundation
Industry and community partners applaud CDC's work to protect people from viral hepatitis, support CDC's efforts through Faces of Hepatitis video stories project
ATLANTA, Aug. 16, 2012 (GLOBE...
GlobeImmune's Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, With the Greatest Effect in the Hardest-to-Treat Patients
April 19, 2010 07:00 ET
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 19, 2010) - GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company's investigational Tarmogen® product for hepatitis C virus (HCV) infection,...
GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV
April 15, 2010 13:00 ET
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, the Company's investigational Tarmogen® product candidate, demonstrating...